Comparative Study on the Effectiveness of Antifungal Agents in Different Regimens against Vaginal Candidiasis

Objective: A study was carried out to compare three treatment regimens for vaginal candidiasis. Methods: A total of 150 women with clinical and mycological evidence of vaginal candidiasis were randomized to receive daily a 200-mg dose of oral itraconazole for 3 days (50 women), a single oral 150 mg dose of fluconazole (50 women), or daily 100 mg dose of intravaginal clotrimazole for 6 days (50 women). They were assessed at 5–15 days (short-term assessment) and again at 30–60 days (long-term assessment) after discontinuation of the treatment. Results: At the short-term or long-term assessment, Candida species were completely eradicated from the vagina in 80 or 74% in the 3-day oral itraconazole group, 76 or 70% in the single oral fluconazole group, and 72 or 60% in the intravaginal clotrimazole group, respectively. The rates of clinical effectiveness were 92 or 88% in the 3-day oral itraconazole group, 80 or 76% in the single oral fluconazole group, and 72 or 58% in the intravaginal clotrimazole group, respectively. Treatment-related side effects were not found in any group. Conclusions: Our study suggests that the treatment of vaginal candidiasis with oral itraconazole or oral fluconazole would be effective and that an oral itraconazole or fluconazole therapy might be one choice in the treatment of vaginal candidiasis.

[1]  Anton C. de Groot Ketoconazole , 2018, Reactions Weekly.

[2]  Kunihiko Ito,et al.  Comparative Study of the Effectiveness of Oral Fluconazole and Intravaginal Clotrimazole in the Treatment of Vaginal Candidiasis , 1995, Infectious diseases in obstetrics and gynecology.

[3]  R. Phillips,et al.  An open multicentre study of the efficacy and safety of a single dose of fluconazole 150 mg in the treatment of vaginal candidiasis in general practice , 1990, The British journal of clinical practice.

[4]  J. Heykants,et al.  Itraconazole: pharmacologic studies in animals and humans. , 1987, Reviews of infectious diseases.

[5]  J. Sobel,et al.  Epidemiology of recurrent vulvovaginal candidiasis: identification and strain differentiation of Candida albicans. , 1986, Journal of Infectious Diseases.

[6]  J. Cutsem,et al.  The in vivo antifungal activity of broad-spectrum azoles , 1986 .

[7]  G. Cauwenbergh,et al.  Itraconazole (R 51 211): A clinical review of its antimycotic activity in dermatology, gynecology, and internal medicine , 1986 .

[8]  P. Troke,et al.  Efficacy of UK-49,858 (fluconazole) against Candida albicans experimental infections in mice , 1985, Antimicrobial Agents and Chemotherapy.

[9]  M J Humphrey,et al.  Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans , 1985, Antimicrobial Agents and Chemotherapy.

[10]  P. Troke,et al.  Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes , 1985, Antimicrobial Agents and Chemotherapy.

[11]  M. Tait Recurrent vaginal candidiasis. , 1985, The New Zealand medical journal.

[12]  J. V. van Cutsem,et al.  Treatment of vaginal candidiasis with ketoconazole, a new, orally active, antimycotic. , 1979, European journal of obstetrics, gynecology, and reproductive biology.

[13]  A. Rogers,et al.  Recurrent Vaginal Candidiasis: Importance of an Intestinal Reservoir , 1977 .

[14]  A. Rogers,et al.  Recurrent vaginal candidiasis. Importance of an intestinal reservoir. , 1977, JAMA.

[15]  J. V. van Cutsem,et al.  The in vivo antifungal activity of broad‐spectrum azoles , 2022 .